Namwiwat Medical PCL (BKK:NAM) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:NAM Namwiwat Medical Corp PCL BKK:NAM
39 GF Score
Price ฿3.40
GF Value ฿5.96
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Namwiwat Medical PCL Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Namwiwat Medical PCL is: No Data: Cannot be evaluated.

Namwiwat Medical PCL  (BKK:NAM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Namwiwat Medical PCL Risk Assessment Related Terms

BKK:NAM vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Namwiwat Medical PCL's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Namwiwat Medical PCL Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Namwiwat Medical PCL's Risk Assessment falls into.


BKK:NAM
39GF Score
Namwiwat Medical Corp PCL BKK:NAM
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?

Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued. The current stock price of ฿3.40 is trading 43% below its estimated GF Value™ of ฿5.96. GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.

Key valuation signals for BKK:NAM:

  • Risk Assessment:
  • GF Value™: ฿5.96 vs. price of ฿3.40 (43% below fair value)
  • GF Score™: 39/100 with 3 warning signs

No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Namwiwat Medical PCL Business Description

Address 999/3-5 Moo 9 Prachauthit - Ku Sang Road, Nai Khlong Bang Pla Kot, Phra Samut Chedi, Samut Prakan, THA, 10290
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
39GF Score

Get the complete analysis for BKK:NAM

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.40
Price
฿5.96
GF Value